S A Quezada
Swanton C, McGranahan N, Starrett G, Harris R. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov. 2015;5:704-12 pubmed publisher
..APOBEC family members might represent a new class of drug target aimed at limiting tumor evolution, adaptation, and drug resistance. ..
Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;: pubmed publisher
..Nevertheless, an evolutionary framework is a powerful aid to understand cancer progression and therapy failure. Indeed, such a framework could be applied to predict individual tumour behaviour and support treatment strategies. ..
Rosenthal R, Cadieux E, Salgado R, Bakir M, Moore D, Hiley C, et al
. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;: pubmed publisher
Turajlic S, McGranahan N, Swanton C. Inferring mutational timing and reconstructing tumour evolutionary histories. Biochim Biophys Acta. 2015;1855:264-75 pubmed publisher
..We discuss how this knowledge can be used to illuminate the genes and pathways that drive cancer initiation and relapse; and to support drug development and clinical trial design. ..
Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez J, et al
. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell. 2018;173:581-594.e12 pubmed publisher
..Finally, we observed early divergence of primitive ancestral clones and protracted latency of up to two decades as a feature of pancreatic metastases. ..
Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et al
. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell. 2018;173:595-610.e11 pubmed publisher
..Our insights reconcile the variable clinical behavior of ccRCC and suggest evolutionary potential as a biomarker for both intervention and surveillance. ..
McGranahan N, Favero F, de Bruin E, Birkbak N, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015;7:283ra54 pubmed publisher
..The frequent presence of subclonal driver mutations suggests the need to stratify targeted therapy response according to the proportion of tumor cells in which the driver is identified. ..
Abbosh C, Birkbak N, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15:577-586 pubmed publisher
..We explain the technical and analytical challenges to low-frequency mutation detection using NGS-based ctDNA profiling and evaluate the feasibility of ctDNA profiling in both screening and MRD assessment contexts. ..
Mitchell T, Turajlic S, Rowan A, Nicol D, Farmery J, O Brien T, et al
. Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell. 2018;173:611-623.e17 pubmed publisher
..Early development of ccRCC follows well-defined evolutionary trajectories, offering opportunity for early intervention. ..